ClinicalTrials.gg
CompletedNCT00756938Updated Jun 18, 2024Results posted

Study of Losartan in Pediatric Patients With Hypertension (MK-0954-337)

A Phase 3 interventional study of losartan potassium in Hypertension, sponsored by Organon and Co. Completed. Open to participants aged 6 Months to 6 Years. Per ClinicalTrials.gov, last updated 2024-06-18.

Sponsored by Organon and Co · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
101
Allocation
Randomized
Ages
6 Months to 6 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 65 studies testing losartan in Hypertension — 5 open to participants now, 5 under way, 1 of them phase 3. Losartan · Hypertension.

Enrollment
31st of 65
101 · median 100
Started
2009
with 1 other
Phase 3
17 of 65
1 open now
Registered
14th of 65
by date
Lead sponsor
7 of 65
Organon and Co

Among the 65 studies testing losartan in Hypertension, this one is the 31st largest by enrollment, is one of 2 that started in 2009, is one of 17 in phase 3, and was the 14th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

5 of the 65 studies testing losartan in Hypertension are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About losartan

Losartan: first FDA approval 1995 (COZAAR). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 6 Months to 6 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 65 studies testing losartan in Hypertension, or all of them as a file.
02

Study summary

This study will explore the dose-response of losartan as well as the safety and tolerability in children from 6 months to 6 years of age.

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
6 Months to 6 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant is determined to be hypertensive

Exclusion criteria

Exclusion Criteria:

  • Participant has a history of severe or symptomatic hypertension
  • Participant has history of heart failure, rhythm disturbance or cardiomyopathy, or obstructive valvular disease
  • Participant has started taking hypertensive medications within the past 30 days
  • Participant has a known sensitivity to losartan or history of angioneurotic edema
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Losartan potassium 0.1 to 1.4 mg/kg

    Open-label losartan at starting dose of 0.1 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved

    Drug: losartan potassium

  • Experimental
    Losartan potassium 0.3 to 1.4 mg/kg

    Open-label losartan at starting dose of 0.3 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved

    Drug: losartan potassium

  • Experimental
    Losartan potassium 0.7 to 1.4 mg/kg

    Open-label losartan at starting dose of 0.7 mg/kg/day with uptitration at Weeks 3, 6, or 9 to the next highest dose level if blood pressure goal not achieved

    Drug: losartan potassium

Interventions

  • losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.

    Also known as: Cozaar

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Systolic Blood Pressure

    Sitting blood pressure (\[BP\] or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Systolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart.

    Time frame: Baseline and Day 21

  2. Number of Participants Who Reported 1 or More Clinical and/or Laboratory Adverse Event(s)

    Time frame: up to 12 weeks (Base Study); up to 24 months (Extension)

  3. Number of Participants Who Were Discontinued From Study Due to a Clinical and/or Laboratory Adverse Event

    Time frame: up to 12 weeks (Base Study); up to 24 months (Extension)

Secondary outcomes

  1. Mean Change From Baseline in Diastolic Blood Pressure

    Sitting BP (or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Diastolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart.

    Time frame: Baseline and Day 21

07

Results

Posted Mar 3, 2014

Participant flow

12-week Base Study
Participant flow — 12-week Base Study
MilestoneLosartan Potassium 0.1 to 1.4 mg/kgLosartan Potassium 0.3 to 1.4 mg/kgLosartan Potassium 0.7 to 1.4 mg/kgLosartan Potassium-Extension
Started3334340
Completed3134320
Not completed2020
Withdrew: Protocol-specific criteria met1010
Withdrew: Protocol violation0010
Withdrew: Lost to follow-up1000
Optional Extension
Participant flow — Optional Extension
MilestoneLosartan Potassium 0.1 to 1.4 mg/kgLosartan Potassium 0.3 to 1.4 mg/kgLosartan Potassium 0.7 to 1.4 mg/kgLosartan Potassium-Extension
Started00090
Completed00053
Not completed00037
Withdrew: Lack of efficacy0001
Withdrew: End of study00011
Withdrew: Protocol-specific criteria met0009
Withdrew: Physician decision0003
Withdrew: Lost to follow-up0001
Withdrew: Protocol violation0001
Withdrew: Withdrawal by subject00010
Withdrew: Adverse event0001

Outcome measures

PrimaryMean Change From Baseline in Systolic Blood Pressure

Sitting blood pressure (\[BP\] or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Systolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart.

Time frame:
Baseline and Day 21
Reported as:
Mean · mmHg
Mean Change From Baseline in Systolic Blood Pressure
mmHgLosartan Potassium 0.1 to 1.4 mg/kgLosartan Potassium 0.3 to 1.4 mg/kgLosartan Potassium 0.7 to 1.4 mg/kg
Mean Change From Baseline in Systolic Blood Pressure-7.31 ± 12.53-7.65 ± 7.49-6.67 ± 7.86
Statistical analysis
  • Losartan Potassium 0.1 to 1.4 mg/kg vs Losartan Potassium 0.3 to 1.4 mg/kg vs Losartan Potassium 0.7 to 1.4 mg/kg · ANCOVA · p = 0.753 · Slope: 1.22 · 95% CI -6.45 to 8.90Analysis of covariance (ANCOVA) model with terms for dose, weight (as a continuous covariate) and presence of co-morbidities/end organ damage
SecondaryMean Change From Baseline in Diastolic Blood Pressure

Sitting BP (or supine if child could not sit) was measured after the participant had been seated for 5 minutes with back supported, feet on the floor and right arm (or left arm if it was the customary side for BP measurement for the patient) supported at heart level. Diastolic BP was determined by averaging 3 replicate measurements obtained at least 1 minute apart.

Time frame:
Baseline and Day 21
Reported as:
Mean · mmHg
Mean Change From Baseline in Diastolic Blood Pressure
mmHgLosartan Potassium 0.1 to 1.4 mg/kgLosartan Potassium 0.3 to 1.4 mg/kgLosartan Potassium 0.7 to 1.4 mg/kg
Mean Change From Baseline in Diastolic Blood Pressure-8.25 ± 11.76-5.15 ± 8.06-6.73 ± 8.59
Statistical analysis
  • Losartan Potassium 0.1 to 1.4 mg/kg vs Losartan Potassium 0.3 to 1.4 mg/kg vs Losartan Potassium 0.7 to 1.4 mg/kg · ANCOVA · p = 0.643 · Slope: 1.81 · 95% CI -5.90 to 9.51Analysis of covariance (ANCOVA) model with terms for dose, weight (as a continuous covariate) and presence of co-morbidities/end organ damage
PrimaryNumber of Participants Who Reported 1 or More Clinical and/or Laboratory Adverse Event(s)
Time frame:
up to 12 weeks (Base Study); up to 24 months (Extension)
Reported as:
Number · Participants
Number of Participants Who Reported 1 or More Clinical and/or Laboratory Adverse Event(s)
ParticipantsBase Study-Losartan Potassium 0.1 mg/kgBase Study-Losartan Potassium 0.3 mg/kgBase Study-Losartan Potassium 0.7 mg/kgBase Study-Losartan Potassium 1.4 mg/kgExtension-Losartan Potassium
Clinical Adverse Event2130362275
Laboratory Adverse Event11005
PrimaryNumber of Participants Who Were Discontinued From Study Due to a Clinical and/or Laboratory Adverse Event
Time frame:
up to 12 weeks (Base Study); up to 24 months (Extension)
Reported as:
Number · Participants
Number of Participants Who Were Discontinued From Study Due to a Clinical and/or Laboratory Adverse Event
ParticipantsBase Study-Losartan Potassium 0.1 mg/kgBase Study-Losartan Potassium 0.3 mg/kgBase Study-Losartan Potassium 0.7 mg/kgBase Study-Losartan Potassium 1.4 mg/kgExtension-Losartan Potassium
Clinical Adverse Event00001
Laboratory Adverse Event00000

Adverse events

Collected over up to 12 weeks (Base Study); up to 24 months (Extension). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Base Study-Losartan Potassium 0.1 mg/kg/Day—3/34 (8.8%)15/34 (44.1%)
Base Study-Losartan Potassium 0.3 mg/kg/Day—2/54 (3.7%)22/54 (40.7%)
Base Study-Losartan Potassium 0.7 mg/kg/Day—2/63 (3.2%)23/63 (36.5%)
Base Study-Losartan 1.4 mg/kg/Day—0/33 (0%)17/33 (51.5%)
Extension-Losartan 0.1 mg/kg/Day—3/15 (20%)12/15 (80%)
Extension-Losartan 0.3 mg/kg/Day—5/28 (17.9%)20/28 (71.4%)
Extension-Losartan 0.7 mg/kg/Day—2/31 (6.5%)20/31 (64.5%)
Extension-Losartan 1.4 mg/kg/Day—5/42 (11.9%)28/42 (66.7%)
Most frequent serious events
Showing 10 of 28
Most frequent serious events
EventBase Study-Losartan Potassium 0.1 mg/kg/DayBase Study-Losartan Potassium 0.3 mg/kg/DayBase Study-Losartan Potassium 0.7 mg/kg/DayBase Study-Losartan 1.4 mg/kg/DayExtension-Losartan 0.1 mg/kg/DayExtension-Losartan 0.3 mg/kg/DayExtension-Losartan 0.7 mg/kg/DayExtension-Losartan 1.4 mg/kg/Day
GastroenteritisInfections and infestations0/340/540/630/330/152/281/311/42
EnteritisGastrointestinal disorders0/340/540/630/331/150/280/310/42
GastritisGastrointestinal disorders0/340/540/630/331/150/280/310/42
Conjunctivitis bacterialInfections and infestations0/340/540/630/331/150/280/310/42
NasopharyngitisInfections and infestations0/340/540/630/331/150/280/310/42
SalmonellosisInfections and infestations0/340/540/630/331/150/280/310/42
Upper respiratory tract infection bacterialInfections and infestations0/340/540/630/331/150/280/310/42
DehydrationMetabolism and nutrition disorders0/340/540/630/330/151/280/310/42
Metabolic acidosisMetabolism and nutrition disorders0/340/540/630/330/151/280/310/42
NephroblastomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/340/540/630/330/151/280/310/42
Most frequent other events
Showing 10 of 42
Most frequent other events
EventBase Study-Losartan Potassium 0.1 mg/kg/DayBase Study-Losartan Potassium 0.3 mg/kg/DayBase Study-Losartan Potassium 0.7 mg/kg/DayBase Study-Losartan 1.4 mg/kg/DayExtension-Losartan 0.1 mg/kg/DayExtension-Losartan 0.3 mg/kg/DayExtension-Losartan 0.7 mg/kg/DayExtension-Losartan 1.4 mg/kg/Day
PharyngitisInfections and infestations3/342/541/631/334/151/280/311/42
DiarrhoeaGastrointestinal disorders2/343/544/632/333/153/285/316/42
Urinary tract infectionInfections and infestations2/342/544/634/330/151/283/317/42
NasopharyngitisInfections and infestations2/347/543/632/332/154/285/312/42
CoughRespiratory, thoracic and mediastinal disorders2/342/542/635/331/151/283/315/42
PyrexiaGeneral disorders3/344/543/631/331/154/282/314/42
Upper respiratory tract infectionInfections and infestations1/343/542/630/331/154/283/314/42
ConjunctivitisEye disorders0/342/541/630/332/150/282/311/42
Acute tonsillitisInfections and infestations0/340/540/630/332/151/281/310/42
Respiratory tract infectionInfections and infestations2/341/545/633/332/153/283/315/42

Baseline characteristics

Age, Continuous
Age, Continuous(Months)Losartan Potassium 0.1 to 1.4 mg/kgLosartan Potassium 0.3 to 1.4 mg/kgLosartan Potassium 0.7 to 1.4 mg/kgTotal
Mean40.2 ± 24.445.0 ± 21.540.6 ± 21.242.0 ± 22.3
Sex: Female, Male
Sex: Female, Male(Participants)Losartan Potassium 0.1 to 1.4 mg/kgLosartan Potassium 0.3 to 1.4 mg/kgLosartan Potassium 0.7 to 1.4 mg/kgTotal
Female13161443
Male20182058
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Webb NJ, Wells TG, Shahinfar S, Massaad R, Dankner WM, Lam C, Santoro EP, McCrary Sisk C, Blaustein RO. A randomized, open-label, dose-response study of losartan in hypertensive children. Clin J Am Soc Nephrol. 2014 Aug 7;9(8):1441-8. doi: 10.2215/CJN.11111113. Epub 2014 May 29. PubMed 24875194 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2009 to primary completion in Aug 2012, 41 months.

Results were first posted in Mar 2014, 1 year 6 months after primary completion. A results delay was requested in Aug 2013.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's 41 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2008
First posted
Sep 22, 2008
StartActual
Mar 1, 2009
Primary completionActual
Aug 14, 2012
CompletionActual
Aug 14, 2012
Results delay requested
Aug 1, 2013
Results first posted
Mar 3, 2014
Last update
Jun 18, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 18, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00756938
Lead sponsor
Organon and Co
Responsible party
Sponsor
First posted
Sep 22, 2008
Start date
Mar 1, 2009
Primary completion
Aug 14, 2012
Completion
Aug 14, 2012
Results posted
Mar 3, 2014
Last update
Jun 18, 2024

Study contacts

Medical Monitor
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Losartan

Start the discussion